CBTN specimen will be used for reduced representation bisulfite sequencing - we will be profiling the transcriptome and epigenome. We will then compare these profiles between boys and girls with pediatric GBM to identify lesions that cause the difference in clinical outcomes of these patients.
What are the goals of this project?
The primary aims of this project are to profile the transcriptome and epigenome and compare between boys and girls.
What is the impact of this project?
This project will aims to identify lesions that cause the difference in clinical outcomes of patients with pediatric GBM.
Why is the CBTN request important to this project?
The Children's Brain Tumor Network provides a unique resource of samples to expand our initial cohort.
The Children's Brain Tumor Network contributed to this project by providing DNA samples.
Sheng Li, PhD
My research interest is to understand the inner workings of cancer cells – the genetic and epigenetic heterogeneity that drive cancer initiation and progression. We utilize computational and sequencing methodologies to identify and characterize the essential epigenetic lesions that guide cancer cell
Christopher E. Mason, PhD
Current Research Interest: New biochemical and computational methods in functional genomics; novel techniques in next-generation sequencing; algorithms for tumor evolution, genome evolution, DNA and RNA modifications; algorithms for genome/epigenome engineering; international standards for clinical-
Weill Cornell Medicine
Jeffrey Greenfield, MD, PhD
Dr. Greenfield’s directs multiple research projects pertaining to pediatric brain tumors, in particular, basic research examining the brain tumor microenvironment, tumor immunology, and precision medicine. This research has been externally funded and widely published and he has received national awa
Weill Cornell Medicine
Weill Cornell MedicineJoined on
The Weill Cornell Medicine Pediatric Brain and Spine Center, located on the Upper East Side campus of New York-Presbyterian/Weill Cornell Medical Center, is nationally recognized for its leadership in the treatment of disorders of the central nervous system in children, particularly brain and spinal
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test